Gold bars to be exempt from tariffs, White House clarifies
NEWTOWN, Pa. - Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company with a market capitalization of $12 million, today announced positive preliminary findings from its latest preclinical study. The company’s stock, currently trading at $3.31, has experienced significant volatility, down 84% over the past year. According to InvestingPro analysis, the company appears slightly undervalued based on its Fair Value assessment. The study involved ferrets infected with the H5N1 bird flu virus, treated with the company’s drug candidate tivoxavir marboxil. This follows previous encouraging results from a murine model in December 2024.
The recent study demonstrated that a single oral dose of tivoxavir marboxil could suppress the disease and reduce the viral burden in the animals’ lungs. "The ferret challenge study builds on the robust protection from bird flu that we observed in a murine model," said C. David Pauza, PhD, Chief Science Officer at Traws Pharma. While the company maintains a healthy current ratio of 1.07 and holds more cash than debt, InvestingPro data indicates the company is quickly burning through its cash reserves.
With bird flu cases on the rise, including human exposures and one fatal case in the USA, the development of effective treatments is becoming increasingly urgent. "We believe safe and effective antiviral drugs will be a critical component in the response to bird flu," commented Robert R. Redfield, MD, Chief Medical (TASE:BLWV) Officer for Traws Pharma.
Traws Pharma is also conducting a similar study in non-human primates, with results expected in the first quarter of 2025. The company plans to discuss an accelerated approval with the FDA, potentially under the Animal Rule, which allows for approval based on animal studies when human trials are not feasible or ethical.
Tivoxavir marboxil is designed to inhibit a protein essential for the influenza virus’s replication. Given the substantial antiviral market opportunity represented by bird flu and seasonal influenza, Traws Pharma’s development of tivoxavir marboxil could play a significant role in addressing these health challenges.
The company intends to provide a detailed review of the bird flu program during a Virtual Investor Update scheduled for March 31, 2025. Investors should note that Traws Pharma’s next earnings report is expected on March 14, 2025, with analysts projecting profitability this year. These developments are based on a press release statement and represent a step forward in the fight against respiratory viral diseases. InvestingPro subscribers have access to 12 additional investment tips and comprehensive financial metrics to better evaluate this emerging biotech opportunity.
In other recent news, Traws Pharma has completed a Phase 1 trial for its investigational oral treatment, tivoxavir marboxil, aimed at treating H5N1 bird flu. The trial demonstrated the drug’s safety and effective blood concentration for over 23 days without any treatment-related adverse events. Additionally, Traws Pharma has secured up to $72.6 million in funding to support its drug development programs, with an initial $20 million already received and the potential for an additional $52.6 million contingent on warrant exercises. The company also regained compliance with Nasdaq’s stockholders’ equity requirement after raising $20 million in a recent financing round, ensuring its continued listing on the NASDAQ Capital Market. Traws Pharma received stockholder approval for the issuance of shares upon the exercise of warrants, allowing the issuance of more than 19.99% of its outstanding common stock. Furthermore, Traws Pharma has amended the terms of its Series A Warrants, adjusting the control change threshold and volatility rate, as well as removing a section related to exercise price adjustments. These developments reflect the company’s ongoing efforts to advance its antiviral programs and secure financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.